Follow us on

Q of the week

Q: Does Indian Patent give protection worldwide?

Get the Answer: 

What is a Boil?
A boil is a skin infection that starts in a hair follicle or oil gland. Also referred to as a skin abscess, it is a localized infection deep in the skin. A boil generally starts as a reddened, tender area. Over time, the area becomes firm and hard. Eventually, the center of the abscess softens and becomes filled with infection-fighting white blood cells that the body sends via the bloodstream to eradicate the infection. This collection of white blood cells, bacteria, and proteins is known as pus. Finally, the pus "forms a head," which can be surgically opened or spontaneously drain out through the surface of the skin.
Welcome to GCP HelpDesk Website 

In this website you will find Good Clinical Practice (GCP) related information for the Clinical Research Industry professionals on request. The GCP HelpDesk is designed to provide information for clinical research professionals with questions regarding handling, conducting and managing clinical research as per GCP, FDA and other Regulations.  This HelpDesk is aimed to provide transparency from resources and expertise in the field of Clinical Research with the recent developments and changes in the guidelines for clinical research professionals. The GCP HelpDesk is a searchable website that will match the question with solution by industry experts and other dedicated sites to a specific area. Both simple and complicated questions are welcomed by the GCP HelpDesk   and we will provide you the answer, if not hope to point you to the one who can. The GCP HelpDesk service is completely free and you can search for required information or by sending an email to GCP Help Desk by including your full name, email address, valid phone number, and a brief description of the problem. We will get back to you through email.

Due to the nature of the clinical research industry and we understand that there is always scope to learn more and improve and we request you to provide your feedback on the design, suggested features or problems and errors you might discover to our team at Feedback  page and we appreciate your suggestion and comments.

Clinical Research Today

FDA approves non-surgical temporary balloon device to treat obesity

The U.S. Food and Drug Administration approved a new balloon device to treat obesity without the need for invasive surgery. The ReShape Integrated Dual Balloon System (ReShape Dual Balloon) is intended to facilitate weight loss in obese adult patients. The device likely works ...


FDA approves diagnostic test to differentiate between types of HIV infection

The U.S. Food and Drug Administration approved the Bio-Rad BioPlex 2200 HIV Ag-Ab assay, the first FDA-approved diagnostic that differentiates between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

Two major types of HIV ...


Australian Public Assessment Reports for prescription medicines (AusPARs)

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

Before a prescription medicine can be made available in Australia, the company legally responsible for supplying ...


FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer

The U.S. Food and Drug Administration approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.

Lung ...


Companies sentenced for supplying hospitals with defective pre-filled syringes

A major healthcare company and a sister company have been sentenced for supplying hospitals with defective pre-filled syringes.

A major healthcare company and a sister company that sold a range of ready-to-use pharmaceutical products it manufactured have been ...


FDA approves new drug to treat heart failure

On 07 Jul 2015, the U.S. Food and Drug Administration drug has been shown to reduce the rate of cardiovascular death and hospitalization related to heart failure.

Heart failure is a common condition affecting about 5.1 million people in the United States. ...


Staying safe when buying medicines online

Patients in the European Union (EU) will now be able to easily identify legally operating online medicine retailers. To help them identify trustworthy sites, an EU-wide logo will appear on the websites of online retailers that are registered in an EU Member ...


FDA approves new treatment for cystic fibrosis

The U.S. Food and Drug Administration approved the first drug for cystic fibrosis directed at treating the cause of the disease in people who have two copies of a specific mutation.

Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) is now approved to treat cystic fibrosis ...


First treatment recommended for rare bone disease

The European Medicines Agency (EMA) has recommended granting a marketing authorisation under exceptional circumstances for Strensiq (asfotase alfa), for the long-term treatment of hypophosphatasia, a rare inherited metabolic disorder affecting the bones, in patients who have developed the disease in childhood.


First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Farydak (panobinostat) for the treatment of multiple myeloma.

Farydak is the first cancer medicine that targets enzymes known as histone deacetylases or HDACs, which are involved in turning genes ...


FDA approves new antiplatelet drug used during heart procedure

On 22 Jun 2015he U.S. Food and Drug Administration approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart. It is approved for adult patients undergoing ...


Opinion Poll

Which one of the following do you think is the most common reason for participating in clinical trials?
This opinion poll provides an informal way for the clinical research community to express its views on current topics. The results are not a scientific poll and do not necessarily reflect the percentages of all clinical researchers who agree with these positions.